US Edition
Published • loading... • Updated
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib showed durable responses across lung, colorectal and pancreatic cancers, with a 58.8% response rate in treatment-naive non-small cell lung cancer, researchers said.
- On Wednesday, April 29, 2026, D3 Bio Inc. reported Phase 2 clinical data for elisrasib at the American Association for Cancer Research Annual Meeting in San Diego, California.
- The next-generation KRAS G12C inhibitor demonstrated robust efficacy at its recommended phase 2 dose of 600 mg across three major tumor types including NSCLC, CRC, and PDAC.
- In NSCLC, elisrasib achieved an ORR of 58.8% with a median progression-free survival of 12.2 months; PDAC patients saw 65.0% ORR with 13.5 months mPFS, while CRC monotherapy showed 46.9% ORR.
- Professor Byoung Chul Cho of Yonsei Cancer Center stated elisrasib "may significantly improve treatment for lung cancer patients with KRAS G12C mutations." Grade 3+ adverse events ranged between 8.7% and 15.6%.
- D3 Bio's pipeline expands beyond elisrasib to include D3S-002, a selective ERK1/2 inhibitor designed for combination approaches to overcome acquired resistance in KRAS-driven tumors.
Insights by Ground AI
39 Articles
39 Articles
The Berkshire Eagle+38 Reposted by 38 other sources
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include:
Coverage Details
Total News Sources39
Leaning Left5Leaning Right7Center16Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 18%
C 57%
R 25%
Factuality
To view factuality data please Upgrade to Premium
